Rifapex, a New Antituberculosis Agent

Сlinісо-roentgenologlc and bacteriologic efficacy and safety of rifapex (rifapentin) were investigated in the complex therapy of 90 patients with newly recorded drug-susceptible tuberculosis. Pifapex was shown to be effective in the treatment of the patients during the acute phase of the disease, du...

Full description

Saved in:
Bibliographic Details
Main Authors: G. B. Sokolova, V. A. Krasnov, T. A. Reikhrud, A. A. Tsybanev
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2020-05-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/203
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849692734201266176
author G. B. Sokolova
V. A. Krasnov
T. A. Reikhrud
A. A. Tsybanev
author_facet G. B. Sokolova
V. A. Krasnov
T. A. Reikhrud
A. A. Tsybanev
author_sort G. B. Sokolova
collection DOAJ
description Сlinісо-roentgenologlc and bacteriologic efficacy and safety of rifapex (rifapentin) were investigated in the complex therapy of 90 patients with newly recorded drug-susceptible tuberculosis. Pifapex was shown to be effective in the treatment of the patients during the acute phase of the disease, during the treatment completeness and during the short preoperative period.
format Article
id doaj-art-873daad2949c4a0888e84bdba2d2cb11
institution DOAJ
issn 0235-2990
language Russian
publishDate 2020-05-01
publisher LLC "Publishing House OKI"
record_format Article
series Антибиотики и Химиотерапия
spelling doaj-art-873daad2949c4a0888e84bdba2d2cb112025-08-20T03:20:37ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902020-05-01541-23841202Rifapex, a New Antituberculosis AgentG. B. Sokolova0V. A. Krasnov1T. A. Reikhrud2A. A. Tsybanev3I.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of TuberculosisI.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of TuberculosisI.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of TuberculosisI.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of TuberculosisСlinісо-roentgenologlc and bacteriologic efficacy and safety of rifapex (rifapentin) were investigated in the complex therapy of 90 patients with newly recorded drug-susceptible tuberculosis. Pifapex was shown to be effective in the treatment of the patients during the acute phase of the disease, during the treatment completeness and during the short preoperative period.https://www.antibiotics-chemotherapy.ru/jour/article/view/203drug susceptible tuberculosiscomplex therapyrifapentin
spellingShingle G. B. Sokolova
V. A. Krasnov
T. A. Reikhrud
A. A. Tsybanev
Rifapex, a New Antituberculosis Agent
Антибиотики и Химиотерапия
drug susceptible tuberculosis
complex therapy
rifapentin
title Rifapex, a New Antituberculosis Agent
title_full Rifapex, a New Antituberculosis Agent
title_fullStr Rifapex, a New Antituberculosis Agent
title_full_unstemmed Rifapex, a New Antituberculosis Agent
title_short Rifapex, a New Antituberculosis Agent
title_sort rifapex a new antituberculosis agent
topic drug susceptible tuberculosis
complex therapy
rifapentin
url https://www.antibiotics-chemotherapy.ru/jour/article/view/203
work_keys_str_mv AT gbsokolova rifapexanewantituberculosisagent
AT vakrasnov rifapexanewantituberculosisagent
AT tareikhrud rifapexanewantituberculosisagent
AT aatsybanev rifapexanewantituberculosisagent